BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 25958847)

  • 1. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease.
    Yamada H; Ohashi K; Suzuki K; Munetsuna E; Ando Y; Yamazaki M; Ishikawa H; Ichino N; Teradaira R; Hashimoto S
    Clin Chim Acta; 2015 Jun; 446():267-71. PubMed ID: 25958847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Free fatty acids, not triglycerides, are associated with non-alcoholic liver injury progression in high fat diet induced obese rats.
    Liu J; Han L; Zhu L; Yu Y
    Lipids Health Dis; 2016 Feb; 15():27. PubMed ID: 26868515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure.
    Zaitone SA; Barakat BM; Bilasy SE; Fawzy MS; Abdelaziz EZ; Farag NE
    Naunyn Schmiedebergs Arch Pharmacol; 2015 Jun; 388(6):587-600. PubMed ID: 25708949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ameliorative effects of lutein on non-alcoholic fatty liver disease in rats.
    Qiu X; Gao DH; Xiang X; Xiong YF; Zhu TS; Liu LG; Sun XF; Hao LP
    World J Gastroenterol; 2015 Jul; 21(26):8061-72. PubMed ID: 26185377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Female spontaneously diabetic Torii fatty rats develop nonalcoholic steatohepatitis-like hepatic lesions.
    Ishii Y; Motohashi Y; Muramatsu M; Katsuda Y; Miyajima K; Sasase T; Yamada T; Matsui T; Kume S; Ohta T
    World J Gastroenterol; 2015 Aug; 21(30):9067-78. PubMed ID: 26290633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats.
    Elshazly SM
    Eur J Pharmacol; 2015 Feb; 748():123-32. PubMed ID: 25542756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis.
    Clarke JD; Sharapova T; Lake AD; Blomme E; Maher J; Cherrington NJ
    J Appl Toxicol; 2014 Jun; 34(6):726-32. PubMed ID: 24217942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and significance of fat mass and obesity associated gene and forkhead transcription factor O1 in non-alcoholic fatty liver disease.
    Zhang J; Li S; Li J; Han C; Wang Z; Li C; Wang X; Liu Z; Wen J; Zheng L
    Chin Med J (Engl); 2014; 127(21):3771-6. PubMed ID: 25382334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phyllanthus Niruri Standardized Extract Alleviates the Progression of Non-Alcoholic Fatty Liver Disease and Decreases Atherosclerotic Risk in Sprague-Dawley Rats.
    Al Zarzour RH; Ahmad M; Asmawi MZ; Kaur G; Saeed MAA; Al-Mansoub MA; Saghir SAM; Usman NS; Al-Dulaimi DW; Yam MF
    Nutrients; 2017 Jul; 9(7):. PubMed ID: 28718838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma.
    Akuta N; Kawamura Y; Suzuki F; Saitoh S; Arase Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Kobayashi M; Ikeda K; Kumada H
    BMC Gastroenterol; 2016 Dec; 16(1):141. PubMed ID: 27955628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats.
    Xu P; Zhang XG; Li YM; Yu CH; Xu L; Xu GY
    J Zhejiang Univ Sci B; 2006 Aug; 7(8):627-33. PubMed ID: 16845716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatoprotective and antioxidant effects of lycopene on non-alcoholic fatty liver disease in rat.
    Jiang W; Guo MH; Hai X
    World J Gastroenterol; 2016 Dec; 22(46):10180-10188. PubMed ID: 28028366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effects of gypenosides against fatty liver disease induced by high fat and cholesterol diet and alcohol in rats.
    Qin R; Zhang J; Li C; Zhang X; Xiong A; Huang F; Yin Z; Li K; Qin W; Chen M; Zhang S; Liang L; Zhang H; Nie H; Ye W
    Arch Pharm Res; 2012 Jul; 35(7):1241-50. PubMed ID: 22864747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanism of geniposide in improving free fatty acid metabolism in rats with non-alcoholic fatty liver disease].
    Liang HQ; Lin MT; Zhao X; Zhou HH; Wang HG; Li GH; Wang YJ; Zhang LM; Wang YY; Chen SD
    Zhongguo Zhong Yao Za Zhi; 2016 Feb; 41(3):470-475. PubMed ID: 28868866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial carnitine palmitoyl transferase-II inactivity aggravates lipid accumulation in rat hepatocarcinogenesis.
    Gu JJ; Yao M; Yang J; Cai Y; Zheng WJ; Wang L; Yao DB; Yao DF
    World J Gastroenterol; 2017 Jan; 23(2):256-264. PubMed ID: 28127199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of glucagon-like peptide-1 on liver oxidative stress, TNF-α and TGF-β1 in rats with non-alcoholic fatty liver disease].
    Gao H; Xu L; Li D; Guang L; Deng W
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Nov; 33(11):1661-4. PubMed ID: 24273273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voluntary oral feeding of rats not requiring a very high fat diet is a clinically relevant animal model of non-alcoholic fatty liver disease (NAFLD).
    Tipoe GL; Ho CT; Liong EC; Leung TM; Lau TY; Fung ML; Nanji AA
    Histol Histopathol; 2009 Sep; 24(9):1161-9. PubMed ID: 19609863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease.
    Yang JM; Sun Y; Wang M; Zhang XL; Zhang SJ; Gao YS; Chen L; Wu MY; Zhou L; Zhou YM; Wang Y; Zheng FJ; Li YH
    World J Gastroenterol; 2019 Sep; 25(34):5105-5119. PubMed ID: 31558860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats.
    Akaslan SB; Degertekin CK; Yilmaz G; Cakir N; Arslan M; Toruner FB
    Metab Syndr Relat Disord; 2013 Aug; 11(4):243-50. PubMed ID: 23544853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.